Session Time: 3:00pm-4:00pm
Disclosures: Hanna Oh, MD: No financial relationships or conflicts of interest
Objective: Amantadine has shown to facilitate recovery after brain injury in adults. Our descriptive retrospective review investigates its use in the pediatric acquired brain injury(ABI) population.
Design: Retrospective chart review Setting : Pediatric Inpatient Rehabilitation Hospital Participants : Total number of subjects admitted with ABI was 105; however only 51 were treated with amantadine(AG) – complete data available on 33 subjects. Complete data is available on 30 subjects admitted with ABI who did not receive amantadine(No-AG).
Interventions: Reviewed the medical records of pediatric patients admitted to an acute inpatient rehabilitation hospital with a diagnosis of ABI between 2011 and 2018.
Main Outcome Measures: Variables include age, admitting diagnosis, admission/discharge WeeFIM. Medical complexity was evaluated by assessing the use of different medications, presence of tracheostomy and/or feeding tube. Duration of amantadine use was compared among subjects with different etiologies of ABI(anoxic brain injury, metabolic encephalopathy, hemorrhagic stroke, traumatic closed-head injury, brain tumors).
Results: Average age of AG was 12.5 and average age of No-AG was 9.6. Gender ratio(M:F) was 17:16 in AG and 19:11 in No-AG. Admission WeeFIM scores(23.94No-AG vs 53.9AG) and discharge WeeFIM(46.12No-AG vs 87.00AG) scores significantly differ. The lower WeeFIM in AG reflects that subjects in AG were more severely involved than No-AG. In AG, 24 subjects had tracheostomies and 24 subjects had feeding tubes compared to only 1 and 4, respectively, in No-AG. Benzodiazepines, opiates, antiepileptics and antihypertensives were more commonly used in AG. Subjects started on amantadine tended to be more medically complex. Change in admission and discharge WeeFIM scores was most variable in patients with traumatic closed-head injury(0-92) and minimal in patients with an anoxic brain injury(0-8). Conclusions: There is a tendency toward starting amantadine in pediatric patients with severe disorders of consciousness. In AG, the smallest improvement in admission-to-discharge WeeFIM was in patients with anoxic brain injury, while the most improvement occurred in patients with traumatic closed-head injury.
Level of Evidence: Level III
To cite this abstract in AMA style:Oh H, Kim H, Huber JE. Current Amantadine Use for Pediatric Acquired Brain Injury in an Acute Pediatric Rehabilitation Hospital – A Retrospective Study [abstract]. PM R. 2020; 12(S1)(suppl 1). https://pmrjabstracts.org/abstract/current-amantadine-use-for-pediatric-acquired-brain-injury-in-an-acute-pediatric-rehabilitation-hospital-a-retrospective-study/. Accessed July 30, 2021.
« Back to AAPM&R Annual Assembly 2020
PM&R Meeting Abstracts - https://pmrjabstracts.org/abstract/current-amantadine-use-for-pediatric-acquired-brain-injury-in-an-acute-pediatric-rehabilitation-hospital-a-retrospective-study/